Abstract：Objective To retrospectively analyze the composition of free antiretroviral therapy (ART) drugs for AIDS in China from 2009 to 2019, it provides policy reference for efficient allocation and reasonable supply of ART free drugs in China, to provide direction guidance for domestic ART drug research and development and production. Methods The information of the types, dosage forms, quantity and procurement methods of ART drugs purchased by centralized bidding with the central public health special fund from January 2009 to December 2019 was collected from the government procurement website of China, indicators such as category composition, frequency and proportion of ART drugs were analyzed annually. Results From 2009 to 2019, there were 10 kinds of free ART drugs in China, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIS). The Staffs was due to be discontinued in 2013, Zidovudine Lamivudine and Efevirenz 200 mg have been used since 2012 and 2018, respectively, the total frequency of drug use increased from 122 400 million in 2009 to 10 814 million in 2019, the use of three types of drugs accounted for the highest proportion of NRTIs (63.46-69.15%), NNRTIs were in the middle (25.66%-32.53%), the lowest PIS (3.15%-7.93%), the PIs class has always been Lopinaviritonavir, in the proportion of single drug dosage, Lamivudine (31.37%), Tenofovir Disofuroxate Fumarate Tablets (23.19%) and Efevirenz (23.05%) were always in the forefront. Conclusion The use of ART drugs is increasing year by year to ensure the accessibility of AIDS treatment; the efficacy of national free ART project has been significantly improved by removing prominent drugs with side effects, including high efficiency single dose and optimizing drug structure; it prompts domestic enterprises to reserve and plan in advance in terms of research and development and production capacity, and also prompts the government to further optimize the composition and policy formulation of ART drugs, and expand the multi-channel drug supply model to solve the supply problem.
马春涛 王强 张煜昆 孟宪宇. 2009—2019年我国艾滋病免费抗病毒治疗药品构成分析[J]. 中国医药导报, 2021, 18(17): 157-160,168.
MA Chuntao WANG Qiang ZHANG Yukun MENG Xianyu. Analysis on the composition of free antiviral drugs for AIDS treatment in China from 2009 to 2019. 中国医药导报, 2021, 18(17): 157-160,168.
[1] 中华人民共和国国家卫生健康委员会，2019年中国艾滋病监测（2019年）[M].北京：中国疾病预防控制中心性病艾滋病预防控制中心，2019，5.
[2] Riddell J，Amico KR，Mayer KH. HIV Preexposure Prophylaxis：A Review [J]. JAMA，2018，319（12）：1261-1268.
[3] 朱金辉，李立明.艾滋病病毒感染者尽早启动抗病毒治疗研究进展[J].应用预防医学，2019，25（4）：344-347， 343.
[4] World Health Organization （WHO），Essential medicines and health products.[EB/OL]. 2021-01. https：//www.who.int/medicines/regulation/medicines-safety/toolkit_indicators/en/.
[5] 晋灿瑞，马春涛，王强，等.中国艾滋病抗病毒治疗药品采购供应现状分析[J].中国公共卫生，2012，28（3）：257-259.
[6] 崔岩，张霞，钱兵，等.中国抗AIDS药物费用现状分析[J].中国艾滋病性病，2009，15（6）：557-559.
[7] 国家药典委员会.中华人民共和国药典[S].二部.北京：中国医药科技出版社，2015，114-117：390-392：633-634.
[8] 中华医学会感染病学分会艾滋病丙型肝炎血族中国疾病预防控制中心.中国艾滋病诊疗指南（2018版）[J].中国艾滋病性病，2018，24（12）：1266-1282.
[9] 国家免费艾滋病抗病毒治疗手册[M].北京，人民卫生出版社，2005，12-45.
[10] 国家免费艾滋病抗病毒治疗手册[M].2版.北京：人民卫生出版社，2008：15-46.
[11] 国家免费艾滋病抗病毒治疗手册[M].3版.北京：人民卫生出版社，2012：14-48.
[12] 国家免费艾滋病抗病毒治疗手册[M].4版.北京：人民卫生出版社，2016：44.
[13] Li L，Ji G，Lin C，et al. Antiretroviral Therapy Initiation Following Policy Changes：Observations From China [J]. Asia Pac J Public Health，2016，28（5）：416-422.
[14] 吴雪韵，沈银忠.艾滋病抗病毒治疗新进展[J].传染病信息，2019，32（1）：81-87.
[15] 豆智慧，张福杰，赵燕，等.2002-2014年中国免费艾滋病抗病毒治疗进展[J].中华流行病学杂志，2015，36（12）：1345-1350.
[16] Polly Clayden. New directions in the 2015 WHO ART guidelines [C]. IAS 8 Vancouver 2015. http：//i-base. Info/hth/28597.
[17] Carey D，Puls R，Amin J，et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily：96-week data from the randomized，double-blind，placebo-controlled，non-inferiority ENCORE1 study [J]. Lancet infect Dis，2015，15（7）：793-802.
[18] Xu L，Peng W，Song X，et al. Pharmacodynamics of efavirenz 400 mg in treatment-na?觙ve Chinese HIV-infected patients in a prospective cohort study [J]. BMC Infect Dis，2021，21（1）：112-121.
[19] 马春涛，霍秀敏，王强.我国艾滋病抗病毒治疗药品注册情况分析[J].中国艾滋病性病，2020，26（9）：32-36.
[20] 刘佳，闫江舟，杨文杰，等.河南省1922例艾滋病一线抗病毒治疗失败患者中HIV耐药基因突变情况分析[J]. 中华预防医学杂志，2015，49（11）：950-955.
[21] 彭新雨，汪宁，徐俊芳，等.深圳市艾滋病抗病毒治疗医保支付情况探索与实践[J].中国艾滋病性病，2019，25（4）：419-420.
[22] 卢珍珍，姜晨晨，倪明健，等.中国艾滋病高效抗病毒治疗研究进展[J].中国公共卫生，2020，4：639-642.
[23] 吴尊友.艾滋病预防技术进展与防治策略[J].中华预防医学杂志，2018，52（12）：1204-1209.
[24] 曾亮，马烨，豆智慧，等.我国艾滋病抗病毒治疗标准调整前后治疗病人生存情况研究[J].中国艾滋病性病，2016， 22（7）：488-492.
[25] Zhang X. Anti-retroviral drugs：current state and development in the next decade [J]. Acta Pharm Sin B，2018， 8（2）：131-136.
[26] Lu DY，Wu HY，Yarla NS，et al. HAART in HIV/AIDS treatments：future Trends [J]. Infect Disord Drug Targets，2018，18（1）：15-22.
京公网安备 11010502046598号